letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH). Harmony’s 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback